B of A Securities Downgrades Lyell Immunopharma to Underperform, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has downgraded Lyell Immunopharma from Buy to Underperform and reduced its price target from $6 to $1.

October 30, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
B of A Securities has downgraded Lyell Immunopharma from Buy to Underperform, significantly lowering the price target from $6 to $1.
The downgrade from Buy to Underperform by a major analyst like B of A Securities is likely to negatively impact investor sentiment and the stock price in the short term. The drastic reduction in the price target from $6 to $1 suggests a lack of confidence in the company's near-term prospects.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100